0001209191-14-020605.txt : 20140314 0001209191-14-020605.hdr.sgml : 20140314 20140314154609 ACCESSION NUMBER: 0001209191-14-020605 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140312 FILED AS OF DATE: 20140314 DATE AS OF CHANGE: 20140314 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AQUINOX PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0001404644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 887 GREAT NORTHERN WAY STREET 2: SUITE 450 CITY: VANCOUVER STATE: A1 ZIP: V5T 4T5 BUSINESS PHONE: 604-629-9223 MAIL ADDRESS: STREET 1: 887 GREAT NORTHERN WAY STREET 2: SUITE 450 CITY: VANCOUVER STATE: A1 ZIP: V5T 4T5 FORMER COMPANY: FORMER CONFORMED NAME: AQUINOX PHARMACEUTICALS (USA) INC DATE OF NAME CHANGE: 20070626 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ventures West 8 Limited Partnership CENTRAL INDEX KEY: 0001599970 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36327 FILM NUMBER: 14694385 BUSINESS ADDRESS: STREET 1: C/O FIVE CORNERS CAPITAL STREET 2: 700 WEST GEORGIA STREET, SUITE 2500 CITY: VANCOUVER STATE: A1 ZIP: V7Y 1B3 BUSINESS PHONE: 360-306-1224 MAIL ADDRESS: STREET 1: C/O FIVE CORNERS CAPITAL STREET 2: 700 WEST GEORGIA STREET, SUITE 2500 CITY: VANCOUVER STATE: A1 ZIP: V7Y 1B3 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-03-12 0 0001404644 AQUINOX PHARMACEUTICALS, INC AQXP 0001599970 Ventures West 8 Limited Partnership C/O FIVE CORNERS CAPITAL 700 W. GEORGIA STREET, SUITE 2500 VANCOUVER A1 V7Y 1B3 BRITISH COLUMBIA, CANADA 0 0 1 0 Common Special Voting Stock 2014-03-12 4 A 0 36502 0.00 A 40147 D Common Special Voting Stock 2014-03-12 4 D 0 40147 0.00 D 0 D Series A-1 Special Voting Stock 2014-03-12 4 D 0 284090 0.00 D 0 D Series A-2 Special Voting Stock 2014-03-12 4 D 0 189393 0.00 D 0 D Series B-1 Special Voting Stock 2014-03-12 4 D 0 326538 0.00 D 0 D Series B-2 Special Voting Stock 2014-03-12 4 D 0 325035 0.00 D 0 D Series C Special Voting Stock 2014-03-12 4 D 0 378786 0.00 D 0 D Common Stock 2014-03-12 4 C 0 1543989 A 1543989 D Common Exchangeable Shares 2014-03-12 4 A 0 36502 11.00 A Common Stock 36502 40147 D Common Exchangeable Shares 2014-03-12 4 C 0 40147 D Common Stock 40147 0 D Series A-1 Exchangeable Shares 2014-03-12 4 C 0 284090 D Series A-1 Preferred Stock 284090 0 D Series A-1 Preferred Stock 2014-03-12 4 C 0 284090 A Common Stock 284090 0 D Series A-1 Preferred Stock 2014-03-12 4 C 0 284090 D Common Stock 284090 0 D Series A-2 Exchangeable Shares 2014-03-12 4 C 0 189393 D Series A-2 Preferred Stock 189393 0 D Series A-2 Preferred Stock 2014-03-12 4 C 0 189393 A Common Stock 189393 0 D Series A-2 Preferred Stock 2014-03-12 4 C 0 189393 D Common Stock 189393 0 D Series B-1 Exchangeable Shares 2014-03-12 4 C 0 326538 D Series B-1 Preferred Stock 326538 0 D Series B-1 Preferred Stock 2014-03-12 4 C 0 326538 A Common Stock 326538 0 D Series B-1 Preferred Stock 2014-03-12 4 C 0 326538 D Common Stock 326538 0 D Series B-2 Exchangeable Shares 2014-03-12 4 C 0 325035 D Series B-2 Preferred Stock 325035 0 D Series B-2 Preferred Stock 2014-03-12 4 C 0 325035 A Common Stock 325035 0 D Series B-2 Preferred Stock 2014-03-12 4 C 0 325035 D Common Stock 325035 0 D Series C Exchangeable Shares 2014-03-12 4 C 0 378786 D Series C Preferred Stock 378786 0 D Series C Preferred Stock 2014-03-12 4 C 0 378786 A Common Stock 378786 0 D Series C Preferred Stock 2014-03-12 4 C 0 378786 D Common Stock 378786 0 D Five Corners Capital Inc., the general partner of Ventures West 8 Limited Partnership, has sole voting and investment power with respect to the shares held by Ventures West 8 Limited Partnership. The directors of Five Corners Capital Inc. are Dr. Gary Bridger and Kenneth Galbraith. Dr. Bridger and Kenneth Galbraith disclaim beneficial ownership of all shares except to the extent of their pecuniary interest. Each share of the issuer's Common, Series A-1, Series A-2, Series B-1, Series B-2 and Series C Special Voting Stock was redeemed upon the closing of the issuer's initial public offering for $0.0000192 per share. Each share of the issuer's Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock converted into Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and has no expiration date. The Common Exchangeable Shares of Aquinox Pharmaceuticals Inc., a corporation under the Canadian Business Corporations Act ("AQXP Canada"), were exchanged for Common Stock of the issuer on a 1-to-1 basis upon the closing of the issuer's initial public offering, and have no expiration date. The Series A-1, Series A-2, Series B-1, Series B-2 and Series C Exchangeable Shares of AQXP Canada were exchanged for Series A-1, Series A-2, Series B-1, Series B-2 and Series C Preferred Stock, respectively, of the issuer on a 1-to-1 basis immediately prior to the closing of the issuer's initial public offering, and have no expiration date. /s/ Gary J. Bridger, Managing Director of Five Corners Capital Inc. 2014-03-14